GlassScriptPhysician profile
Shilka Surendra Babu
NPI 1407413651
$2,527.71
in general payments reported to CMS, 2019-2025
20 companies · $797 in 2025
The $797 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $137 · 2023: $785 · 2024: $809 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,390.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $394.00 | 2024-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $384.71 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $363.39 | 2023-2025 | Qulipta, Ubrelvy, Synthroid |
| Novo Nordisk INC | $227.10 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $205.96 | 2023-2025 | |
| Amgen INC. | $193.89 | 2023-2025 | Repatha, Otezla, Evenity |
| Abiomed | $134.67 | 2023 | Impella |
| Glaxosmithkline, LLC. | $115.78 | 2023-2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Dynavax Technologies Corporation | $100.13 | 2024-2025 | Heplisav-B |
| Inspire Medical Systems, INC. | $82.83 | 2023-2024 | Inspire |
| Merck Sharp & Dohme LLC | $76.25 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Aimmune Therapeutics, INC. | $50.65 | 2025 | Zenpep |
| Bayer Healthcare Pharmaceuticals INC. | $36.44 | 2025 | |
| Idorsia Pharmaceuticals US INC | $30.37 | 2022-2023 | Quviviq |
| Radius Health, INC. | $29.36 | 2025 | Tymlos |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $24.90 | 2025 | Tirosint, Flector, Licart |
| Exact Sciences Corporation | $23.89 | 2025 | |
| Astellas Pharma US INC | $18.81 | 2024 | Veozah |
| Neos Therapeutics, LP | $17.31 | 2024 | Adzenys Xr-Odt |
| Optinose US, INC. | $17.27 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shilka Babu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.